Acer Therapeutics Compliant with All Nasdaq Listing Criteria
Acer Therapeutics Inc. (Nasdaq: ACER) has confirmed that it has regained compliance with Nasdaq's $35 million market value requirement for continued listing on the Nasdaq Capital Market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Acer Therapeutics Inc. (Nasdaq: ACER) has confirmed that it has regained compliance with Nasdaq's $35 million market value requirement for continued listing on the Nasdaq Capital Market. This notification means the previously scheduled hearing before the Nasdaq Hearings Panel has been canceled. Acer focuses on developing therapies for rare and life-threatening diseases, with its product OLPRUVA™ approved for treating urea cycle disorders. The company also has several investigational candidates in its pipeline for various serious conditions.
Positive
- Acer has regained compliance with Nasdaq's $35 million market value requirement.
- The scheduled hearing for Nasdaq compliance has been canceled.
Negative
- None.
Details
News Market Reaction – ACER
The recorded move for ACER in the trading session of this news was +1.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the
About Acer Therapeutics
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the treatment of urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Acer is also advancing a pipeline of investigational product candidates for rare and life-threatening diseases, including: OLPRUVA™ (sodium phenylbutyrate) for treatment of various other inborn errors of metabolism, including Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS) and Post-traumatic Stress Disorder (PTSD); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, Zika, dengue, Ebola and COVID-19. For more information, visit www.acertx.com.
Acer Contacts
Corporate contact:
Jim DeNike
Acer Therapeutics Inc.
jdenike@acertx.com
+1-844-902-6100
Investor contact:
Nick Colangelo
Gilmartin Group
nick@gilmartinIR.com
+1-332-895-3226
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.